

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Neurology</b>				
Multiple sclerosis (MS)	Annexin A1 (ANXA1)	<p>Patient sample and mouse studies suggest ANXA1 could help restore blood brain barrier (BBB) integrity in patients with MS. In mice, <i>Anxa1</i> knockout increased BBB permeability compared with no knockout. In the same mice, i.v. infusion of recombinant human ANXA1 decreased BBB permeability compared with no treatment. Cerebral capillaries from patients who have MS showed selective loss of ANXA1, whereas capillaries from healthy donors did not. Next steps include analyzing ANXA1 levels in blood samples from patients at different stages of MS to see if the protein could be a useful biomarker.</p> <p><b>SciBX 6(3); doi:10.1038/scibx.2013.64</b>  <b>Published online Jan. 24, 2013</b></p>	Work unpatented; models available for licensing	<p>Cristante, E. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Dec. 31, 2012;  doi:10.1073/pnas.1209362110  <b>Contact:</b> Egle Solito, University of London, London, U.K.  e-mail:  <a href="mailto:e.solito@qmul.ac.uk">e.solito@qmul.ac.uk</a></p>